Schaumburg-based APP Pharmaceuticals Inc. will begin marketing a breast cancer treatment medication in the U.S. as Anastrozole, the drug’s generic name. Anastrozole tablets, also known as Arimidex , are mainly used to treat early breast cancer in post-menopausal women.

APP’s parent company, Fresenius Kabi Pharmaceuticals Holding Inc., said the move comes after the U.S. Food and Drug Administration granted its research company permission to market the drug.